Galapagos N.V.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GLPG research report →
Companywww.glpg.com
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.
- CEO
- Henry Gosebruch
- IPO
- 2012
- Employees
- 704
- HQ
- Mechelen, BE
Price Chart
Valuation
- Market Cap
- $1.80B
- P/E
- 3.09
- P/S
- 1.45
- P/B
- 0.46
- EV/EBITDA
- 2.71
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.01%
- Op Margin
- 55.43%
- Net Margin
- 46.83%
- ROE
- 16.28%
- ROIC
- 17.67%
Growth & Income
- Revenue
- $1.11B · 303.50%
- Net Income
- $320.88M · 333.15%
- EPS
- $4.85 · 333.04%
- Op Income
- $501.39M
- FCF YoY
- 49.67%
Performance & Tape
- 52W High
- $37.78
- 52W Low
- $24.74
- 50D MA
- $30.32
- 200D MA
- $32.15
- Beta
- 0.25
- Avg Volume
- 181.66K
Get TickerSpark's AI analysis on GLPG
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our GLPG Coverage
We haven't published any research on GLPG yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GLPG Report →